Q-LINEA

Reportable ranges for antimicrobials and bacteria covered by ASTar BC G– Kit (US). Dots indicate where MIC results and interpretations (when applicable) will be presented.

Antimicrobial class	Antimicrobial agent	*A. baumanii* complex	*C. freundii* complex	*C. koseri*	*E. cloacae* complex	*E. coli*	*K. aerogenes*	*K. oxytoca*	*K. pneumoniae* group	*M. morganii*	*P. mirabilis*	*P. vulgaris*	*S. marcescens*	*P. aeruginosa*
Penicillin	Ampicillin					●					●			
β-lactam combination agents	Ampicillin-sulbactam[1]	●		●		●		●	●	●	●	●		
β-lactam combination agents	Ceftolozane-tazobactam		●	●	●	●		●	●		●	●	●	●
β-lactam combination agents	Ceftazidime-avibactam[2]		●	●	●	●	●	●	●	●	●	●	●	●
β-lactam combination agents	Meropenem-vaborbactam[3]		●	●	●	●	●	●	●	●	●	●	●	
β-lactam combination agents	Piperacillin-tazobactam[4]	●	●	●		●	●		●	●	●	●	●	
Cephalosporin	Cefazolin			●		●		●	●		●			
Cephalosporin	Cefepime		●	●	●	●	●	●	●		●	●	●	●
Cephalosporin	Cefotaxime		●	●	●	●		●	●		●	●	●	
Cephalosporin	Ceftriaxone		●	●	●	●	●	●	●		●	●	●	
Cephalosporin	Cefoxitin			●		●		●	●		●			
Cephalosporin	Cefuroxime			●		●		●	●		●			
Cephalosporin	Ceftazidime	●	●	●	●	●	●	●	●	●	●	●	●	
Monobactam	Aztreonam		●	●	●	●	●	●	●	●	●	●	●	●
Carbapenem	Ertapenem		●	●	●	●		●	●		●	●	●	
Carbapenem	Meropenem	●	●	●	●	●	●	●	●	●	●	●	●	●
Aminoglycoside	Gentamicin		●	●				●	●	●	●	●	●	
Aminoglycoside	Tobramycin		●	●	●	●	●	●	●		●	●		●
Aminoglycoside	Amikacin	●	●	●	●	●	●	●	●	●	●	●	●	
Tetracycline	Tigecycline		●	●	●	●	●	●	●				●	
Fluoroquinolone	Ciprofloxacin		●	●	●	●	●	●	●	●	●	●	●	●
Fluoroquinolone	Levofloxacin		●	●	●	●	●	●	●	●	●	●	●	●
Miscellaneous	Trimethoprim-sulfamethoxazole[5]		●	●	●	●	●	●	●	●		●		

[1] Ampicillin-sulbactam in the ratio 2:1
[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 µg/mL
[3] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 µg/mL
[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 µg/mL
[5] Trimethoprim:sulfamethoxazole in the ratio 1:19

Q-LINEA

Antimicrobial reportable ranges for AST and FDA-recognized/approved clinical breakpoints, i.e. susceptible (S), intermediate (I), susceptible-dose dependent (SDD) and resistant (R).

Antimicrobial agent	ASTar BC G-Reportable range (µg/mL)	Organism Group	FDA-Recognized / Approved Breakpoints (µg/mL) S	I/SDD	R
Amikacin	≤2 to ≥256 ≤0.5 to ≥256[1]	*A. baumannii* complex Enterobacterales	≤8 ≤4	16 8	≥32 ≥16
Ampicillin	≤1 to ≥128	Enterobacterales	≤8	16	≥32
Ampicillin-sulbactam	≤1 to ≥128[2]	*A. baumannii* complex Enterobacterales	≤8	16	32
Aztreonam	≤0.25 to ≥128[3] ≤0.5 to ≥128	Enterobacterales *P. aeruginosa*	≤4 ≤8	8 16	≥16 ≥32
Cefazolin	≤0.25 to ≥32	Enterobacterales	≤2	4	≥8
Cefepime	≤0.25 to ≥128	Enterobacterales *P. aeruginosa*	≤2 ≤8	4-8[4] 16	≥16 ≥32
Cefotaxime	≤0.25 to ≥16	Enterobacterales	≤1	2	≥4
Cefoxitin	≤1 to ≥128	Enterobacterales	≤4	8	≥16
Ceftazidime	≤0.5 to ≥128 ≤0.25 to ≥128[5]	*A. baumannii* complex Enterobacterales	≤8 ≤4	16 8	≥32 ≥16
Ceftazidime-avibactam	≤0.125 to ≥64[6] ≤0.125 to ≥64	Enterobacterales *P. aeruginosa*	≤8	-	≥16
Ceftolozane-tazobactam	≤0.25 to ≥64	Enterobacterales *P. aeruginosa*	≤2 ≤4	4 8	≥8 ≥16
Ceftriaxone	≤0.25 to ≥16	Enterobacterales	≤1	2	≥4
Cefuroxime	≤1 to ≥128	Enterobacterales	≤8	-	≥16
Ciprofloxacin	≤0.125 to ≥16	Enterobacterales *P. aeruginosa*	≤0.25 ≤0.5	0.5 1	≥1 ≥2
Ertapenem	≤0.06 to ≥16	Enterobacterales	≤0.5	1	≥2
Gentamicin	≤0.25 to ≥64	Enterobacterales	≤2	4	≥8
Levofloxacin	≤0.125 to ≥32	Enterobacterales *P. aeruginosa*	≤0.5 ≤1	1 2	≥2 ≥4
Meropenem	≤0.06 to ≥128 ≤0.06 to ≥128[7] ≤0.06 to ≥128	*A. baumannii* complex Enterobacterales *P. aeruginosa*	≤2 ≤1 ≤2	4 2 4	≥8 ≥4 ≥8
Meropenem-vaborbactam	≤0.25 to ≥64[8]	Enterobacterales	≤4	8	≥16
Piperacillin-tazobactam	≤1 to ≥512 ≤0.25 to ≥512[9]	*A. baumannii* complex Enterobacterales	≤16 ≤8	32-64 16	≥128 ≥32
Tigecycline	≤0.03 to ≥32	Enterobacterales	≤2	4	≥8
Tobramycin	≤0.06 to ≥64[10] ≤0.125 to ≥64	Enterobacterales *P. aeruginosa*	≤2 ≤1	4 2	≥8 ≥4
Trimethoprim-sulfamethoxazole	≤0.06 to ≥16[11]	Enterobacterales	≤2	-	≥4

[1] AST Reportable range for Amikacin is ≤2 to ≥256 µg/mL for *C. koseri*, *E. coli*, *M. morganii* and *P. vulgaris*.
[2] AST Reportable range for Ampicillin-sulbactam is ≤2 to ≥128 µg/mL for *P. vulgaris*.
[3] AST Reportable range for Aztreonam is ≤0.5 to ≥128 µg/mL for *C. freundii* complex, *E. coli* and *M. morganii*.
[4] Interpretive category results for Cefepime/Enterobacterales are susceptible-dose dependent (SDD).
[5] AST Reportable range for Ceftazidime is ≤0.5 to ≥128 µg/mL for *C. freundii* complex, *C. koseri*, *K. aerogenes* and *M. morganii*.
[6] AST Reportable range for Ceftazidime-avibactam is ≤1 to ≥64 µg/mL for *E. coli*, *K. aerogenes*, *K. pneumoniae* group, *M. morganii* and *P. vulgaris*.
[7] AST Reportable range for Meropenem is ≤0.125 to ≥64 µg/mL for *E. cloacae* complex, *K. aerogenes*, *K. oxytoca*, *K. pneumoniae* group and *M. morganii*.
[8] AST Reportable range for Meropenem-vaborbactam is ≤0.5 to ≥64 µg/mL for *M. morganii* and *P. vulgaris*.
[9] AST Reportable range for Piperacillin-tazobactam is ≤1 to ≥512 µg/mL for *C. freundii* complex, *E. coli*, *K. aerogenes*, *K. pneumoniae* group and *M. morganii*.
[10] AST Reportable range for Tobramycin is ≤0.125 to ≥64 µg/mL for *K. aerogenes*, *K. oxytoca*, *K. pneumoniae* group and *P. vulgaris*.
[11] AST Reportable range for Trimethoprim-sulfamethoxazole is ≤0.25 to ≥16 µg/mL for *C. freundii* complex, *C. koseri* and *M. morganii*.

www.qlinea.com